Compile Data Set for Download or QSAR
Report error Found 4366 Enz. Inhib. hit(s) with Target = 'Protein arginine N-methyltransferase 5'
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM579105(US11492351, Example 16-8 | US11479551, Example 16-...)
Affinity DataKd:  0.00900nMAssay Description:Binding affinity to human PRMT5 assessed as dissociation constant in presence of SAM by SPR analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/7/2023
Entry Details Article
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM415557(US10428104, Example 88)
Affinity DataKi:  0.0200nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50597886(CHEMBL5180177)
Affinity DataKi:  0.0200nMAssay Description:Binding affinity to PRMT5 (unknown origin) assessed as inhibition constantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50597880(CHEMBL5203719)
Affinity DataIC50: 0.130nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50462572(CHEMBL4249337)
Affinity DataIC50: 0.140nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2025
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50462572(CHEMBL4249337)
Affinity DataIC50: 0.140nMAssay Description:Inhibition of full-length human N-terminal FLAG-tagged PRMT5 expressed in Sf9 insect cells using histone H2A as peptide after 120 mins in presence of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/19/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50523646(CHEMBL4541714)
Affinity DataIC50: 0.160nMAssay Description:Inhibition of PRMT5 in human A549 cells assessed as reduction in sDMA production after 48 hrs by Hoechst Stain/HCS CellMask Deep Red Stain based immu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50462572(CHEMBL4249337)
Affinity DataIC50: 0.25nMAssay Description:Inhibition of PRMT5 in human A549 cells assessed as reduction in sDMA production after 48 hrs by Hoechst Stain/HCS CellMask Deep Red Stain based immu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50238541(CHEMBL4092336)
Affinity DataIC50: 0.330nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50523641(CHEMBL4543007)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of PRMT5 in human A549 cells assessed as reduction in sDMA production after 48 hrs by Hoechst Stain/HCS CellMask Deep Red Stain based immu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50597881(CHEMBL5187591)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/22/2023
Entry Details
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50637554(CHEMBL5560909)
Affinity DataIC50: 0.420nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50612685(CHEMBL5283866)
Affinity DataIC50: 0.420nMAssay Description:Inhibition of human PRMT5 by fluorescence-based SAHH-coupled assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50637320(CHEMBL5559161)
Affinity DataIC50: 0.420nMAssay Description:Inhibition of PRMT5 (unknown origin) by HotSpot profiling analysisMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/11/2025
Entry Details
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50566330(CHEMBL4874774)
Affinity DataEC50: <0.5nMAssay Description:Inhibition of PRMT5 (unknown origin) assessed as inhibition of symmetric dimethylation of arginine incubated for 3 days by fluorescence based cellula...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2022
Entry Details Article
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM435525(US10570140, Example 12 | (2R,3S,4R,5R)-2-(((2-amin...)
Affinity DataIC50: 0.5nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2022
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50566349(CHEMBL4854745)
Affinity DataEC50:  0.740nMAssay Description:Inhibition of PRMT5 (unknown origin) assessed as inhibition of symmetric dimethylation of arginine incubated for 3 days by fluorescence based cellula...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2022
Entry Details Article
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM435509(US10570140, Example 1 | (2R,3S,4R,5R)-5-(4-amino-7...)
Affinity DataIC50: 0.75nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2022
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50462572(CHEMBL4249337)
Affinity DataIC50: 0.772nMAssay Description:Inhibition of PRMT5 (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2024
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM435657(US10570140, Example 55 | (2R,3S,4R,5R)-2-(((2-amin...)
Affinity DataIC50: 0.800nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2022
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50623919(CHEMBL5422317)
Affinity DataIC50: 0.800nMAssay Description:Inhibition of PRMT5 in human Z138 cells assessed as decrease in sDMA modification incubated for 2 days by fluorescence based assayMore data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
12/17/2024
Entry Details
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50566352(CHEMBL4861625)
Affinity DataEC50:  0.840nMAssay Description:Inhibition of PRMT5 (unknown origin) assessed as inhibition of symmetric dimethylation of arginine incubated for 3 days by fluorescence based cellula...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2022
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM435523(US10570140, Example 6 | (2R,3S,4R,5R)-5-(4-amino-5...)
Affinity DataIC50: 0.850nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2022
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50566347(CHEMBL4867460)
Affinity DataEC50:  0.870nMAssay Description:Inhibition of PRMT5 (unknown origin) assessed as inhibition of symmetric dimethylation of arginine incubated for 3 days by fluorescence based cellula...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2022
Entry Details Article
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50566348(CHEMBL4852843)
Affinity DataEC50:  0.890nMAssay Description:Inhibition of PRMT5 (unknown origin) assessed as inhibition of symmetric dimethylation of arginine incubated for 3 days by fluorescence based cellula...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2022
Entry Details Article
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50566323(CHEMBL4860414)
Affinity DataEC50:  0.900nMAssay Description:Inhibition of PRMT5 (unknown origin) assessed as inhibition of symmetric dimethylation of arginine incubated for 3 days by fluorescence based cellula...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2022
Entry Details Article
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM435710(US10570140, Example 68 | (2R,3S,4R,5R)-5-(4-amino-...)
Affinity DataIC50: 0.900nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (50 mM Tris-HCl, pH 8.5,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/16/2022
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50566350(CHEMBL4873949)
Affinity DataEC50:  0.970nMAssay Description:Inhibition of PRMT5 (unknown origin) assessed as inhibition of symmetric dimethylation of arginine incubated for 3 days by fluorescence based cellula...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2022
Entry Details Article
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451282(US10709709, Example 109)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451280(US10709709, Example 107)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451281(US10709709, Example 108)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451278(US10709709, Example 105)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451276(US10709709, Example 103)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451277(US10709709, Example 104)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451274(US10709709, Example 101)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451275(US10709709, Example 102)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451273(US10709709, Example 100)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451298(US10709709, Example 125)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451299(US10709709, Example 126)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM415554(US10428104, Example 85 | (2R,3R,4S,5R)-2-(4-amino-...)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/17/2020
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451294(US10709709, Example 121)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451292(US10709709, Example 119)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451293(US10709709, Example 120)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM452998((2R,3R,4S,5S)-2-(4-amino- 7H-pyrrolo[2,3-d]pyrimid...)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM50645828(CHEMBL5594198)
Affinity DataKd:  1nMAssay Description:Binding affinity to apo PRMT5 (1 to 637 residues)(unknown origin) expressed in baculovirus infected Sf21 insect cells assessed as dissociation consta...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/12/2025
Entry Details
PubMed
TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451286(US10709709, Example 113)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM452999((2S,3S,4R,5R)-2-((R)-6- chloro-1,3- dihydroisobenz...)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized and 3-fold diluted in 100% DMSO. These diluted compounds were further diluted in the assay buffer (20 mM Tris-HCl, pH 8.0,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2022
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451312(US10709709, Example 139)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451306(US10709709, Example 133)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

TargetProtein arginine N-methyltransferase 5(Human)
Mirati Therapeutics

Curated by ChEMBL
LigandPNGBDBM451307(US10709709, Example 134)
Affinity DataIC50: 1nMAssay Description:Compounds were solubilized in DMSO and serially diluted, using 3-fold dilutions, into 100% DMSO at a concentration 50-fold greater than the desired a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2021
Entry Details
US Patent

Displayed 1 to 50 (of 4366 total ) | Next | Last >>
Jump to: